Subscribe to newsletters
Biogen Stocks Surge Amidst Delay in Eli Lilly’s Alzheimer’s Treatment
Shares of Biogen (BIIB) soared on Friday following news of a setback in the approval process for Eli Lilly’s (LLY) competing Alzheimer’s treatment, donanemab. The Food and Drug Administration (FDA) had been expected to make a decision on donanemab this…